In the sorafenib/erlotinib arm versus the sorafenib/placebo arm , the overall response rate trended higher ( 6.6 % v 3.9 % , respectively ; P = .102 ) , whereas the disease control rate was significantly lower ( 43.9 % v 52.5 % , respectively ; P = .021 ) .